dc.contributor.author | Yalman, N | |
dc.contributor.author | Devecioglu, O | |
dc.contributor.author | Eryilmaz, E | |
dc.contributor.author | Anak, S | |
dc.contributor.author | Gedikoglu, G | |
dc.contributor.author | Sarper, N | |
dc.contributor.author | Ozbek, U | |
dc.contributor.author | Agaoglu, L | |
dc.contributor.author | Ozgen, U | |
dc.date.accessioned | 2021-03-03T09:58:33Z | |
dc.date.available | 2021-03-03T09:58:33Z | |
dc.date.issued | 2000 | |
dc.identifier.citation | Sarper N., Ozbek U., Agaoglu L., Ozgen U., Eryilmaz E., Yalman N., Anak S., Devecioglu O., Gedikoglu G., "Is AML1/ETO gene expression a good prognostic factor in pediatric acute myeloblastic leukemia?", PEDIATRIC HEMATOLOGY AND ONCOLOGY, cilt.17, sa.7, ss.577-583, 2000 | |
dc.identifier.issn | 0888-0018 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_1ff88e53-0034-4931-922d-83c06270e944 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/26579 | |
dc.identifier.uri | https://doi.org/10.1080/08880010050122843 | |
dc.description.abstract | To assess the clinical significance of AML1/ETO gene detected by nested reverse transcriptase polymerase chain reaction, the outcome of 7 patients with acute myeloblastic leukemia between 3 and 14 years of age were presented. All patients had complete remission (CR) at the end of induction (AML-MRC 10 protocol) and 4 underwent unpurged autologous, 2 allogeneic (from matced siblings) non-T-cell-depleted bone marrow transplantations (BMT) in first CR. One patient died due to allogeneic BMT-related complications, and 4 patients relapsed at 13, 17, 18, and 26 months. Only one patient achieved second CR. All relapsed patients died between 18 and 36 months with resistant disease (n = 3) or infection during salvage chemotherapy (n = 1). Two patients who had autologous BMT are alive and disease free at 44 and 50 months. Although statistical significance could not be shown, event-free survival and overall survival rates of AML1/ETO-positive patients (28.57 and 28.57 %, respectively) at 3.5 years were even lower than those of AML1/ETO-negative patients. The results confirm some previous reports that AML1/ETO gene in children and adolescents is not a favorable prognostic factor. | |
dc.language.iso | eng | |
dc.subject | Çocuk Sağlığı ve Hastalıkları | |
dc.subject | İç Hastalıkları | |
dc.subject | Hematoloji | |
dc.subject | Onkoloji | |
dc.subject | PEDİATRİ | |
dc.subject | HEMATOLOJİ | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Klinik Tıp | |
dc.subject | ONKOLOJİ | |
dc.title | Is AML1/ETO gene expression a good prognostic factor in pediatric acute myeloblastic leukemia? | |
dc.type | Makale | |
dc.relation.journal | PEDIATRIC HEMATOLOGY AND ONCOLOGY | |
dc.contributor.department | , , | |
dc.identifier.volume | 17 | |
dc.identifier.issue | 7 | |
dc.identifier.startpage | 577 | |
dc.identifier.endpage | 583 | |
dc.contributor.firstauthorID | 126584 | |